CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 at 1:40 p.m. PDT.
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 at 1:40 p.m. PDT. A live webcast will be available on the company's Investors "Events & Presentations" page, with a replay archived for 14 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CRSP
In the May 6 session, CRSP gained 5.15%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- May 12, 2026
- Bank of America Securities 2026 Global Healthcare Conference presentation
- Presentation time
- 1:40 p.m. PDT
- Scheduled time for fireside chat webcast
- Webcast replay period
- 14 days
- Replay archived on company website after presentation
Historical Context
-
Reported Q1 2026 results, CASGEVY revenue, cash of $2.44B, ongoing losses.
-
Announced Needham healthcare conference presentation and webcast details.
-
Priced upsized $550M 2031 convertible notes plus $50M option.
-
Proposed $350M 2031 convertible notes with $52.5M option for corporate use.
-
Reported Q4 and 2025 results with CASGEVY revenue and pipeline progress.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.